Structural studies of antitumor compounds that target the RING domain of MDM2. (21st July 2022)

• Record Type: Journal Article
• Authors: Terrell, James Ross; Tang, Sijia; Faniyi, Oluwafoyinsola Omobodunde; Jeong, In Ho; Yin, Jun; Nijampatnam, Bhavitavya; Velu, Sadanandan E.; Wang, Wei; Zhang, Ruiwen; Luo, Ming
• Is Part Of: Protein science. Volume 31:Number 8(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-21
• Subjects: crystal structure -- drug design -- E3 ubiquitin ligase -- inhibition mechanism -- RING finger protein; Proteins -- Periodicals; 572.6
• DOI: 10.1002/pro.4367
• Languages: English
• ISSNs: 0961-8368

Abstract

Abstract: Mouse double minute 2 homolog (MDM2) is an E3 ubiquitin‐protein ligase that is involved in the transfer of ubiquitin to p53 and other protein substrates. The expression of MDM2 is elevated in cancer cells and inhibitors of MDM2 showed potent anticancer activities. Many inhibitors target the p53 binding domain of MDM2. However, inhibitors such as Inulanolide A and MA242 are found to bind the RING domain of MDM2 to block ubiquitin transfer. In this report, crystal structures of MDM2 RING domain in complex with Inulanolide A and MA242 were solved. These inhibitors primarily bind in a hydrophobic site centered at the sidechain of Tyr489 at the C‐terminus of MDM2 RING domain. The C‐terminus of MDM2 RING domain, especially residue Tyr489, is required for ubiquitin discharge induced by MDM2. The binding of these inhibitors at Tyr489 may interrupt interactions between the MDM2 RING domain and the E2‐Ubiquitin complex to inhibit ubiquitin transfer, regardless of what the substrate is. Our results suggest a new mechanism of inhibition of MDM2 E3 activity for a broad spectrum of substrates. Abstract : PDB Code(s): 7T59, 7TFG and 7THL ;